Home Healthcare Market Analysis By Component {Equipment (Therapeutic, Diagnostic, Mobility Assist)}, Services (Rehabilitation, Unskilled Home Care, Respiratory Therapy Services, Infusion Therapy Services, Telemetry), And Segment Forecasts, 2014 - 2025

The global home healthcare market is expected to reach USD 517.2 billion by 2025, according to a new report by Grand View Research, Inc. Home healthcare products are generally applied to a broad range of equipment and services designed for exclusive use for home or other non-medical establishments by non-professional caregivers, family members, or the patients themselves.

Increasing adoption of telehealth and other emerging technologies are expected to drive market growth over the forecast period. Home healthcare is rapidly getting adopted as a cost effective alternative to healthcare establishment based therapy and therefore, growing geriatric population base and prevalence of chronic conditions requiring long term care is also expected to have a positive impact on growth. Presence of untapped potential in emerging markets such as India, Brazil and China and increasing health awareness are expected to serve home healthcare market as future growth opportunities.

Further key findings from the study suggest:

Home healthcare services dominated the component segment, accounting for over 85.0% of global revenue in 2015.

Infusion therapy is expected to be the fastest growing services market. Increasing initiatives undertaken by medical service providers to curb costs associated with specialty drugs and by retail pharmacies to render efficient chronic disease management solutions are some of the drivers of this market.

Home healthcare based diagnostics held lucrative share in the equipment segment accounting around 40.0% in 2015.

North America was the largest regional market in 2015, accounting for over 40.0% of the revenue. Presence of sophisticated medical systems and reimbursement infrastructure, high patient awareness levels and healthcare expenditure are some of the factors accounting for its substantial share.

Asia Pacific home healthcare market is expected to grow at the fastest CAGR of around 9.0% from 2016 to 2024 majorly owing to high unmet medical needs coupled with rapidly improving health infrastructure.

Major players in this vertical include Almost Family Inc., B. Braun Melsungen AG, Abbott Laboratories, Sunrise Medical Inc., 3M Health Care, Baxter, Medtronic, Cardinal Health Inc., Roche diagnostics corp., Air Liquide, Arcadia Health Care, Bayer AG, Amedisys, Inc., Nxstage Medical, Inc., and Arkray Inc.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
Chapter 3. Home Healthcare Market Variables, Trends & Scope
3.1. Market Segmentation & Scope
3.2. Market Driver Analysis
3.3. Penetration & Growth Prospect Mapping
3.4. SWOT Analysis, By Factor
3.4.1. Political
3.4.2. Economic
3.4.3. Technological
3.5. Industry Analysis - Porter’s
Chapter 4. Home Healthcare Component Estimates & Trend Analysis
4.1. Home Healthcare Movement Analysis & Market Share, 2015 & 2025
4.2. Market Size Estimates & Forecasts and Trend Analyses, 2014 to 2025 (USD Billion) for the Following Components:
4.2.1. Equipment
4.2.1.1. Therapeutic
4.2.1.1.1. Home Respiratory Equipment
4.2.1.1.2. Insulin Delivery Device
4.2.1.1.3. Home IV Pumps
4.2.1.1.4. Home Dialysis Equipment
4.2.1.1.5. Other Therapeutic Equipment
4.2.1.2. Diagnostics
4.2.1.2.1. Diabetic Care Unit
4.2.1.2.2. BP Monitors
4.2.1.2.3. Multi Parameter Diagnostic Monitors
4.2.1.2.4. Home Pregnancy and Fertility Kits
4.2.1.2.5. Other Self-Monitoring Equipment
4.2.1.2.6. Apnea and Sleep Monitors
4.2.1.2.7. Holter Monitors
4.2.1.2.8. Heart Rate Maters
4.2.1.2.9. Other
4.2.1.3. Mobility Assists
4.2.1.3.1. Rehabilitation Services
4.2.1.3.2. Unskilled Home Care
4.2.1.3.3. Respiratory Therapy Services
4.2.1.3.4. Infusion Therapy Services
4.2.1.3.5. Telemetry
4.2.2. Services
4.2.2.1.1. Rehabilitation Services
4.2.2.1.2. Unskilled Home Care
4.2.2.1.3. Respiratory Therapy Services
4.2.2.1.4. Infusion Therapy Services
4.2.2.1.5. Telemetry
Chapter 5. Home Healthcare Regional Estimates & Trend Analysis
5.1. Regional Movement Analysis & Market Share, 2015 & 2025
5.2. North America
5.2.1. U.S.
5.2.1.1. U.S. revenue estimates and forecasts by, component (USD Billion) 2014 - 2025
5.2.2. Canada
5.2.2.1. Canada revenue estimates and forecasts by, component (USD Billion) 2014 - 2025
5.3. Europe
5.3.1. UK
5.3.1.1. UK revenue estimates and forecasts by, component (USD Billion) 2014 - 2025
5.3.2. Germany
5.3.2.1. Germany revenue estimates and forecasts by, component (USD Billion) 2014 - 2025
5.4. Asia Pacific
5.4.1. Japan
5.4.1.1. Japan revenue estimates and forecasts by, component (USD Billion) 2014 - 2025
5.4.2. China
5.4.2.1. China revenue estimates and forecasts by, component (USD Billion) 2014 - 2025
5.5. Latin America
5.5.1. Brazil
5.5.1.1. Brazil revenue estimates and forecasts by, component (USD Billion) 2014 - 2025
5.5.2. Mexico
5.5.2.1. Mexico revenue estimates and forecasts by, component (USD Billion) 2014 - 2025
5.6. MEA
5.6.1. South Africa
5.6.1.1. South Africa revenue estimates and forecasts by, component (USD Billion) 2014 - 2025
Chapter 6. Competitive Landscape
6.1. Strategy Framework
6.2. Company Profiles
6.2.1. Almost Family Inc.
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Product Benchmarking
6.2.1.4. Strategic Initiatives
6.2.2. B. Braun Melsungen AG
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Product Benchmarking
6.2.2.4. Strategic Initiatives
6.2.3. Abbott Laboratories
6.2.3.1. Company Overview
6.2.3.2. Financial Performance
6.2.3.3. Product Benchmarking
6.2.3.4. Strategic Initiatives
6.2.4. Sunrise Medical Inc.
6.2.4.1. Company Overview
6.2.4.2. Financial Performance
6.2.4.3. Product Benchmarking
6.2.4.4. Strategic Initiatives
6.2.5. 3M Healthcare
6.2.5.1. Company Overview
6.2.5.2. Financial Performance
6.2.5.3. Product Benchmarking
6.2.5.4. Strategic Initiatives
6.2.6. Baxter International Inc.
6.2.6.1. Company Overview
6.2.6.2. Financial Performance
6.2.6.3. Product Benchmarking
6.2.6.4. Strategic Initiatives
6.2.7. Medtronic
6.2.7.1. Company Overview
6.2.7.2. Financial Performance
6.2.7.3. Product Benchmarking
6.2.7.4. Strategic Initiatives
6.2.8. Cardinal Health Inc.
6.2.8.1. Company Overview
6.2.8.2. Financial Performance
6.2.8.3. Product Benchmarking
6.2.8.4. Strategic Initiatives
6.2.9. Roche Diagnostics Corp.
6.2.9.1. Company Overview
6.2.9.2. Financial Performance
6.2.9.3. Product Benchmarking
6.2.9.4. Strategic Initiatives
6.2.10. Roche Diagnostics Corp.
6.2.10.1. Company Overview
6.2.10.2. Financial Performance
6.2.10.3. Product Benchmarking
6.2.10.4. Strategic Initiatives
6.2.11. Roche Diagnostics Corp.
6.2.11.1. Company Overview
6.2.11.2. Financial Performance
6.2.11.3. Product Benchmarking
6.2.11.4. Strategic Initiatives
6.2.12. Air Liquide
6.2.12.1. Company Overview
6.2.12.2. Financial Performance
6.2.12.3. Product Benchmarking
6.2.12.4. Strategic Initiatives
6.2.13. Arcadia Resources, Inc.
6.2.13.1. Company Overview
6.2.13.2. Financial Performance
6.2.13.3. Product Benchmarking
6.2.13.4. Strategic Initiatives
6.2.14. Bayer Healthcare AG
6.2.14.1. Company Overview
6.2.14.2. Financial Performance
6.2.14.3. Product Benchmarking
6.2.14.4. Strategic Initiatives
6.2.15. Amedisys, Inc.
6.2.15.1. Company Overview
6.2.15.2. Financial Performance
6.2.15.3. Product Benchmarking
6.2.15.4. Strategic Initiatives
6.2.16. Nxstage Medical, Inc
6.2.16.1. Company Overview
6.2.16.2. Financial Performance
6.2.16.3. Product Benchmarking
6.2.16.4. Strategic Initiatives
6.2.17. Arkray Inc.
6.2.17.1. Company Overview
6.2.17.2. Financial Performance
6.2.17.3. Product Benchmarking
6.2.17.4. Strategic Initiatives
6.2.18. Apria Healthcare Group
6.2.18.1. Company Overview
6.2.18.2. Financial Performance
6.2.18.3. Product Benchmarking
6.2.18.4. Strategic Initiatives
6.2.19. Odyssey Healthcare Inc.
6.2.19.1. Company Overview
6.2.19.2. Financial Performance
6.2.19.3. Product Benchmarking
6.2.19.4. Strategic Initiatives
6.2.20. Becton, Dickinson and Company
6.2.20.1. Company Overview
6.2.20.2. Financial Performance
6.2.20.3. Product Benchmarking
6.2.20.4. Strategic Initiatives
6.2.21. Critical Homecare
6.2.21.1. Company Overview
6.2.21.2. Financial Performance
6.2.21.3. Product Benchmarking
6.2.21.4. Strategic Initiatives
6.2.22. National Healthcare Corp.
6.2.22.1. Company Overview
6.2.22.2. Financial Performance
6.2.22.3. Product Benchmarking
6.2.22.4. Strategic Initiatives
6.2.23. Omron Healthcare, Inc.
6.2.23.1. Company Overview
6.2.23.2. Financial Performance
6.2.23.3. Product Benchmarking
6.2.23.4. Strategic Initiatives
6.2.24. Drive Medical Design & Manufacturing
6.2.24.1. Company Overview
6.2.24.2. Financial Performance
6.2.24.3. Product Benchmarking
6.2.24.4. Strategic Initiatives
6.2.25. Chubb Community Care
6.2.25.1. Company Overview
6.2.25.2. Financial Performance
6.2.25.3. Product Benchmarking
6.2.25.4. Strategic Initiatives
6.2.26. Gambro AB
6.2.26.1. Company Overview
6.2.26.2. Financial Performance
6.2.26.3. Product Benchmarking
6.2.26.4. Strategic Initiatives
6.2.27. GE Healthcare
6.2.27.1. Company Overview
6.2.27.2. Financial Performance
6.2.27.3. Product Benchmarking
6.2.27.4. Strategic Initiatives
6.2.28. Medline Industries Inc.
6.2.28.1. Company Overview
6.2.28.2. Financial Performance
6.2.28.3. Product Benchmarking
6.2.28.4. Strategic Initiatives
6.2.29. Philips Healthcare
6.2.29.1. Company Overview
6.2.29.2. Financial Performance
6.2.29.3. Product Benchmarking
6.2.29.4. Strategic Initiatives
6.2.30. Medco Health Solutions Inc.
6.2.30.1. Company Overview
6.2.30.2. Financial Performance
6.2.30.3. Product Benchmarking
6.2.30.4. Strategic Initiatives
6.2.31. Graham-Field Health Products Inc.
6.2.31.1. Company Overview
6.2.31.2. Financial Performance
6.2.31.3. Product Benchmarking
6.2.31.4. Strategic Initiatives
6.2.32. Hill-Rom Holdings Inc.
6.2.32.1. Company Overview
6.2.32.2. Financial Performance
6.2.32.3. Product Benchmarking
6.2.32.4. Strategic Initiatives
6.2.33. Gentiva Health Services Inc
6.2.33.1. Company Overview
6.2.33.2. Financial Performance
6.2.33.3. Product Benchmarking
6.2.33.4. Strategic Initiatives
6.2.34. Johnson & Johnson
6.2.34.1. Company Overview
6.2.34.2. Financial Performance
6.2.34.3. Product Benchmarking
6.2.34.4. Strategic Initiatives
6.2.35. Linde Healthcare
6.2.35.1. Company Overview
6.2.35.2. Financial Performance
6.2.35.3. Product Benchmarking
6.2.35.4. Strategic Initiatives
6.2.36. Lincare Holdings, Inc.
6.2.36.1. Company Overview
6.2.36.2. Financial Performance
6.2.36.3. Product Benchmarking
6.2.36.4. Strategic Initiatives
6.2.37. Kinetic Concepts
6.2.37.1. Company Overview
6.2.37.2. Financial Performance
6.2.37.3. Product Benchmarking
6.2.37.4. Strategic Initiatives
6.2.38. Carefusion
6.2.38.1. Company Overview
6.2.38.2. Financial Performance
6.2.38.3. Product Benchmarking
6.2.38.4. Strategic Initiatives
6.2.39. Vygon
6.2.39.1. Company Overview
6.2.39.2. Financial Performance
6.2.39.3. Product Benchmarking
6.2.39.4. Strategic Initiatives
6.2.40. Teleflex
6.2.40.1. Company Overview
6.2.40.2. Financial Performance
6.2.40.3. Product Benchmarking
6.2.40.4. Strategic Initiatives
6.2.41. Moog Inc.
6.2.41.1. Company Overview
6.2.41.2. Financial Performance
6.2.41.3. Product Benchmarking
6.2.41.4. Strategic Initiatives
6.2.42. Intersurgical
6.2.42.1. Company Overview
6.2.42.2. Financial Performance
6.2.42.3. Product Benchmarking
6.2.42.4. Strategic Initiatives
6.2.43. Fresenius Kabi
6.2.43.1. Company Overview
6.2.43.2. Financial Performance
6.2.43.3. Product Benchmarking
6.2.43.4. Strategic Initiatives